Blood Gases Versus Lactate Clearance as an Indicator of Initial Resuscitation in Septic Patients: Comparative Study
NCT ID: NCT05049941
Last Updated: 2021-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2021-08-15
2021-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ratio of ''Central Venous-to-Arterial Co2 Gap'' to ''Arterial-to-Central Venous O2 Content Gap'' in Septic Shock
NCT04425161
Microcirculatory Oxygen Uptake in Sepsis
NCT02430142
The PvCO2-PaCO2/CaO2-CvO2 Ratio in Septic Shock
NCT07096284
Role of PCO2 Gap as Predictor of Clinical Outcome in ICU Septic Patients
NCT06256198
Temporal Changes of Lactate in CLASSIC Patients
NCT05629780
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group (3):
veno-arterial carbon dioxide tension group; P(v-a)co2 difference Measurements were obtained at T0 (before the start of resuscitation) and at T8 (after 8 hours of the start of resuscitation), the three groups received the same initial resuscitation protocol according to Surviving Sepsis Campaign (9), the appropriate specimens were taken for aerobic and anaerobic culture, empirical broad-spectrum antibiotics was given, source of infection was controlled with removal of any old intravascular lines which may be the source of sepsis.
The early goals of resuscitation were to achieve the following: CVP of 8-12 cmH2O, MAP \> 65 mm Hg, a urine output \>0.5 mL/kg and Scvo2 of 70% or more, we started with 30 ml/kg crystalloids in the first 3 hours, then we guided by hemodynamic status, if not achieved, we were targeted by titrating vasopressors until MAP \> 65 mmHg by using either norepinephrine (0.25 mcg /kg/min increasing every 15 min) or dobutamine (2.5 mcg/min every 15 min increased). The patients connected to mechanical ventilation if needed with appropriate settings, with minimal dose of sedation, blood glucose controlled and anticoagulant and Proton pump inhibitors were administrated as a prophylaxis, early enteral nutrition was initiated, if there was no contraindications Measured data
In group (1) we prepared this measures at T0 and T8:
* The arteriovenous oxygen content difference (C(a-v)O2) C(a-v)O2 = Cao2 - Cvo2
* The venoarterial CO2 tension difference (P(v-a)CO2) P(v-a)CO2 = Pvco2 - Paco2
* P(v-a)CO2/C(a-v)O2 ratio
* (Pvco2 - Paco2)/(Cao2 - Cvo2)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group1
Group (1): veno-arterial carbon dioxide tension / arteriovenous oxygen content P(v-a)CO2/C(a-v)O2 ratio group.
lactat and blood gases
observational
group 2
Group (2): Lactate clearance (LC) group; Lactate level was measured then LC rate was calculated by the equation \[(lactate(T0)- lactate(T8))/lactate(T0)\] × 100%.
lactat and blood gases
observational
group 3
Group (3):
veno-arterial carbon dioxide tension group; P(v-a)co2 difference
lactat and blood gases
observational
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lactat and blood gases
observational
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Hassanein Mohamed
assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ahmed hassanein, MD
Role: PRINCIPAL_INVESTIGATOR
Minia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Hassanein
Minya, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6382021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.